Celsion (NSDQ:CLSN) and Children’s National Health System are teaming up to tackle refractory solid tumors in pediatric patients using a heat-activated chemotherapy drug and noninvasive ultrasound. The Phase I clinical trial, which launched last November, is the 1st of its kind in the U.S.
Lawrenceville, N.J.-based Celsion’s ThermoDox is a heat-activated liposomal doxorubicin. In combination with MRI, high-intensity focused ultrasound is used to direct sound wave energy and heat the tumor. When the liposomal chemotherapy drug comes into contact with the heated tumor, the liposome changes structure and releases doxorubicin into the tumor.
Get the full story at our sister site, Drug Delivery Business News.
The post Celsion’s ThermoDox activated by ultrasound in pediatric cancer study appeared first on MassDevice.
from MassDevice http://ift.tt/2jjQDgK
Cap comentari:
Publica un comentari a l'entrada